Mayo Test Catalog, (Sorted By Test Name) - Mayo Medical ...

ALPS
82449
sensitization to particular allergens prior to beginning immunotherapy, and to investigate the specificity of
allergic reactions to insect venom allergens, drugs, or chemical allergens.
Interpretation: Detection of IgE antibodies in serum (Class 1 or greater) indicates an increased
likelihood of allergic disease as opposed to other etiologies and defines the allergens that may be
responsible for eliciting signs and symptoms. The level of IgE antibodies in serum varies directly with
the concentration of IgE antibodies expressed as a class score or kU/L.
Reference Values:
Class IgE kU/L Interpretation
0 Negative
1 0.35-0.69 Equivocal
2 0.70-3.49 Positive
3 3.50-17.4 Positive
4 17.5-49.9 Strongly positive
5 50.0-99.9 Strongly positive
6 > or =100 Strongly positive Reference values
apply to all ages.
Clinical References: Homburger HA: Allergic diseases. In Clinical Diagnosis and Management
by Laboratory Methods. 21st edition. Edited by McPherson RA, Pincus MR. WB Saunders, Publ, New
York, 2007 Chapter 53, Part VI, pp 961-971
Alpha Beta Double-Negative T Cells for Autoimmune
Lymphoproliferative Syndrome
Clinical Information: Autoimmune lymphoproliferative syndrome (ALPS) (also known as
Canale-Smith syndrome) is a complex clinical disorder of dysregulated lymphocyte homeostasis that is
characterized by lymphoproliferative disease, autoimmune cytopenias, splenomegaly, and
lymphadenopathy with an increased susceptibility to malignancy.(1) Typically, ALPS is diagnosed by
childhood or young adulthood. Genetic defects in the apoptosis (programmed cell death) pathway have
been determined for most cases of ALPS. Apoptosis plays a role in normal immune homeostasis by
limiting lymphocyte accumulation and autoimmune reactivity. The interaction of the surface receptor
CD95 (FAS) and its ligand (CD95L;FASL) triggers the apoptotic pathway in lymphocytes. The
following molecular ALPS classification has been established: ALPS Classification Molecular/Genetic
Defect in Apoptosis Type Ia CD95 (FAS) mutations(1) Type Ib Heterozygous CD95L (FASLG)
mutations(1) Type Ic Homozygous CD95L (FASLG) mutation(2) Type II CASP8 or CASP10
mutations(1,3) Type III Unknown(1,3) Patients with ALPS have an increase in a normally rare
population of T cells (typically